Advantages and Limitations of Current Biomarker Research: From Experimental Research to Clinical Application

被引：25

作者：

Kim, Seung-Hyun ^{[1
]}

Weiss, Christel ^{[2
]}

Hoffmann, Ursula ^{[1
]}

Borggrefe, Martin ^{[1
]}

Akin, Ibrahim ^{[1
]}

Behnes, Michael ^{[1
]}

机构：

[1] Heidelberg Univ, Fac Med Mannheim, Univ Med Ctr Mannheim UMM, Dept Med 1, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany

[2] Heidelberg Univ, Fac Med Mannheim, Univ Med Ctr Mannheim UMM, Dept Stat Anal, Mannheim, Germany

来源：

CURRENT PHARMACEUTICAL BIOTECHNOLOGY | 2017年 / 18卷 / 06期

关键词：

Cardiovascular disease; heart failure; acute coronary syndrome; biomarker; proteome; metabolome; micro-RNA; ACUTE CORONARY SYNDROMES; ACUTE HEART-FAILURE; C-REACTIVE PROTEIN; CARDIAC RESYNCHRONIZATION THERAPY; BRAIN NATRIURETIC PEPTIDE; LEFT-VENTRICULAR FUNCTION; SENSITIVITY TROPONIN-T; CIRCULATING MICRORNAS; PROGNOSTIC VALUE; RISK STRATIFICATION;

D O I：

10.2174/1389201018666170601091205

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: Biomarkers are indispensable tools for screening, diagnosis, and prognosis in cardiovascular diseases and their clinical application increases steadily. As cardiovascular diseases include various pathophysiological processes, no single biomarker, even natriuretic peptides, can be regarded as ideal fulfilling all necessary criteria for a comprehensive diagnostic or prognostic assessment revealing optimal clinical application. Hence, multi-marker approaches using different biomarkers reflecting different pathophysiologies were highlighted recently. Advances in biomedical technologies expanded the spectrum of novel blood-derived biomarkers, such as micro-RNA (miRNA) or "omics"data potentially providing a more advanced knowledge about pathogenesis of cardiovascular disease. Conclusion: This review describes the advantages and limitations of blood circulating biomarkers with regard to proteins, metabolomics and transcriptional level both within single as well as multi-marker strategies. Moreover, their usefulness is focused on clinical decision-making in cardiovascular diseases.

引用

页码：445 / 455

页数：11

共 125 条

[1] Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers [J].

Akat, Kemal Marc ;

Moore-McGriff, D'Vesharronne ;

Morozova, Pavel ;

Browna, Miguel ;

Gogakos, Tasos ;

Da Rosa, Joel Correa ;

Mihailovic, Aleksandra ;

Sauer, Markus ;

Ji, Ruiping ;

Ramarathnam, Aarthi ;

Totary-Jain, Hana ;

Williams, Zev ;

Tuschl, Thomas ;

Schulze, P. Christian .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (30) :11151-11156

[2] Metabolomics and Incidence of Atrial Fibrillation in African Americans: The Atherosclerosis Risk in Communities (ARIC) Study [J].

Alonso, Alvaro ;

Yu, Bing ;

Qureshi, Waqas T. ;

Grams, Morgan E. ;

Selvin, Elizabeth ;

Soliman, Elsayed Z. ;

Loehr, Laura R. ;

Chen, Lin Y. ;

Agarwal, Sunil K. ;

Alexander, Danny ;

Boerwinkle, Eric .

PLOS ONE, 2015, 10 (11)

[3] C-reactive protein in heart failure - Prognostic value and the effect of valsartan [J].

Anand, IS ;

Latini, R ;

Florea, VG ;

Kuskowski, MA ;

Rector, T ;

Masson, S ;

Signorini, S ;

Mocarelli, P ;

Hester, A ;

Glazer, R ;

Cohn, JN .

CIRCULATION, 2005, 112 (10) :1428-1434

[4] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[5] Caveats of Untargeted Metabolomics for Biomarker Discovery [J].

Baig, Ferheen ;

Pechlaner, Raimund ;

Mayr, Manuel .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (12) :1294-1296

[6] Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy [J].

Bang, Claudia ;

Batkai, Sandor ;

Dangwal, Seema ;

Gupta, Shashi Kumar ;

Foinquinos, Ariana ;

Holzmann, Angelika ;

Just, Annette ;

Remke, Janet ;

Zimmer, Karina ;

Zeug, Andre ;

Ponimaskin, Evgeni ;

Schmiedl, Andreas ;

Yin, Xiaoke ;

Mayr, Manuel ;

Halder, Rashi ;

Fischer, Andre ;

Engelhardt, Stefan ;

Wei, Yuanyuan ;

Schober, Andreas ;

Fiedler, Jan ;

Thum, Thomas .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (05) :2136-2146

[7]

Barallobre-Barreiro J, 2013, REV ESP CARDIOL, V66, P657, DOI [10.1016/j.recesp.2013.04.010, 10.1016/j.rec.2013.04.009]

[8] Use of serum levels of high sensitivity troponin T, galectin-3 and C-terminal propeptide of type I procollagen at long term follow-up in heart failure patients with reduced ejection fraction: Comparison with soluble AXL and BNP [J].

Batlle, M. ;

Campos, B. ;

Farrero, M. ;

Cardona, M. ;

Gonzalez, B. ;

Castel, M. A. ;

Ortiz, J. ;

Roig, E. ;

Pulgarin, M. J. ;

Ramirez, J. ;

Bedini, J. L. ;

Sabate, M. ;

de Frutos, P. Garcia ;

Perez-Villa, F. .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 225 :113-119

[9] Multiple biomarker strategies for risk stratification in heart failure [J].

Bayes-Genis, Antoni ;

Ordonez-Llanos, Jordi .

CLINICA CHIMICA ACTA, 2015, 443 :120-125

[10] Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure [J].

Bayes-Genis, Antoni ;

de Antonio, Marta ;

Galan, Amparo ;

Sanz, Hector ;

Urrutia, Agustin ;

Cabanes, Roser ;

Cano, Lucia ;

Gonzalez, Beatriz ;

Diez, Cristanto ;

Pascual, Teresa ;

Elosua, Roberto ;

Lupon, Josep .

EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (01) :32-38

← 1 2 3 4 5 6 7 8 9 10 →